LIVING MODIFIED ORGANISM (LMO)

BCH-LMO-SCBD-108045-1

? Decisions on the LMO ? Risk Assessments

LAST UPDATED: 15 MAY 2015

Living Modified Organism identity

The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.



Name

Domestic goat modified to produce human lactoferrin	EN

Transformation event

rhLF Goat

Developer(s)

- PERSON: DR ALEXANDER IVANOVICH BUDEVICH | BCH-CON-BY-108026-2

PERSON

Dr Alexander Ivanovich Budevich
head of laboratory, Laboratory of reproduction, embryo transfer and animal transgenesis
Frunze,11
Zhodino, Minsk district
222167, Belarus
Phone: +375177522184
Fax: +375177535283
Email: belniig@tut.by
Website: http://belniig.by/

RELATED ORGANIZATION

Description

A human lactoferrin coding sequence was incorporated into the goat genome resulting in the synthesis of the biologically active glycoprotein, rhLF, in the mammary gland of the transgenic goats.	EN

Recipient Organism or Parental Organisms

The term “Recipient organism” refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas “Parental organisms” refers to those that were involved in cross breeding or cell fusion.

BCH-ORGA-SCBD-108041-2 ORGANISM | CAPRA AEGAGRUS HIRCUS (DOMESTIC GOAT, GOAT, CAPHI) | Mammals

Characteristics of the modification process

Vector

hLf3, hLf5 EN

Techniques used for the modification

Microinjection

Introduced or modified genetic element(s)

Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.

BCH-GENE-SCBD-108043-1 RECOMBINANT HUMAN LACTOFERRIN CODING SEQUENCE | (HUMANS) | Protein coding sequence | Production of medical or pharmaceutical compounds (human or animal)

BCH-GENE-SCBD-108044-1 BETA-CASEIN GENE PROMOTER | (DOMESTIC GOAT, GOAT, CAPHI) | Promoter

LMO characteristics

Modified traits

Production of medical or pharmaceutical compounds (human or animal)

Common use(s) of the LMO

Research

BCH-LMO-SCBD-108045-1

Further Information

Questions about the Cartagena Protocol on Biosafety or the operation of the Biosafety Clearing-House may be directed to the Secretariat of the Convention on Biological Diversity.

Secretariat of the Convention on Biological Diversity
413 rue Saint-Jacques, suite 800
Montreal, Québec, H2Y 1N9
Canada
Fax: +1 514 288-6588
Email: secretariat@cbd.int